Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RGNX Stock 12 Month Forecast
Average Price Target
$24.25
▲(82.88% Upside)
| Highest Price Target$37.00 | Average Price Target$24.25 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$34
Buy
156.41%
Upside
Reiterated
11/17/25
RegenXBio's Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price TargetValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $1.76B. This includes a discounted cash flow (DCF) analysis-based asset value of $1.65B for ABBV-RGX-314, RGX-121 ad RGX-202, using a 20% discount rate and 1% terminal growth rate, $302.0M cash, and excludes $191.6M liability related to sale of future royalties. Assigned probabilities of approval are 55% in wet AMD, 40% in DR, 65% in MPS in DMD. Assuming 51.4M shares outstanding at the end of 3Q26, this yields a value of approximately $34 per share.
Bank of America Securities
$20
Buy
50.83%
Upside
Reiterated
11/14/25
RegenXBio's Strategic Manufacturing Edge and Market Position Justify Buy RatingWe came away from the visit positive on the end-to-end capabilities and ability to safely provide doses at commercial scale with attractive COGS. With today’s updated Elevidys label reinforcing the unmet need in DMD and supporting the accelerated approval pathway, we see an attractive commercial opportunity with a majority of the prevalent population likely available for Regenxbio at launch. We maintain Buy and $20 PO. High % full capsids, large scale to support commercial opp.
Morgan Stanley
$24→$25
Buy
88.54%
Upside
Reiterated
11/07/25
Barclays
$37
Buy
179.03%
Upside
Reiterated
11/07/25
RBC Capital
$17→$19
Buy
43.29%
Upside
Reiterated
11/06/25
Stifel Nicolaus
―
Buy
―
Reiterated
11/03/25
Leerink Partners
$17→$16
Buy
20.66%
Upside
Reiterated
09/15/25
Raymond James
$29
Buy
118.70%
Upside
Reiterated
09/05/25
Goldman Sachs
$14
Hold
5.58%
Upside
Reiterated
09/05/25
Clear Street
$50
Buy
277.07%
Upside
Initiated
03/31/25
Robert W. Baird
$39
Buy
194.12%
Upside
Reiterated
03/19/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$34
Buy
156.41%
Upside
Reiterated
11/17/25
RegenXBio's Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price TargetValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $1.76B. This includes a discounted cash flow (DCF) analysis-based asset value of $1.65B for ABBV-RGX-314, RGX-121 ad RGX-202, using a 20% discount rate and 1% terminal growth rate, $302.0M cash, and excludes $191.6M liability related to sale of future royalties. Assigned probabilities of approval are 55% in wet AMD, 40% in DR, 65% in MPS in DMD. Assuming 51.4M shares outstanding at the end of 3Q26, this yields a value of approximately $34 per share.
Bank of America Securities
$20
Buy
50.83%
Upside
Reiterated
11/14/25
RegenXBio's Strategic Manufacturing Edge and Market Position Justify Buy RatingWe came away from the visit positive on the end-to-end capabilities and ability to safely provide doses at commercial scale with attractive COGS. With today’s updated Elevidys label reinforcing the unmet need in DMD and supporting the accelerated approval pathway, we see an attractive commercial opportunity with a majority of the prevalent population likely available for Regenxbio at launch. We maintain Buy and $20 PO. High % full capsids, large scale to support commercial opp.
Morgan Stanley
$24→$25
Buy
88.54%
Upside
Reiterated
11/07/25
Barclays
$37
Buy
179.03%
Upside
Reiterated
11/07/25
RBC Capital
$17→$19
Buy
43.29%
Upside
Reiterated
11/06/25
Stifel Nicolaus
―
Buy
―
Reiterated
11/03/25
Leerink Partners
$17→$16
Buy
20.66%
Upside
Reiterated
09/15/25
Raymond James
$29
Buy
118.70%
Upside
Reiterated
09/05/25
Goldman Sachs
$14
Hold
5.58%
Upside
Reiterated
09/05/25
Clear Street
$50
Buy
277.07%
Upside
Initiated
03/31/25
Robert W. Baird
$39
Buy
194.12%
Upside
Reiterated
03/19/25
Best Analysts Covering RegenXBio
1 Month
xxx
Success Rate
9/15 ratings generated profit
Average Return
+8.05%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +8.05% per trade.
3 Months
xxx
Success Rate
6/12 ratings generated profit
Average Return
+1.59%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.59% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+2.28%
reiterated a buy rating 3 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +2.28% per trade.
2 Years
xxx
Success Rate
7/12 ratings generated profit
Average Return
+9.99%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 58.33% of your transactions generating a profit, with an average return of +9.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RGNX Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
20
21
19
18
14
Buy
1
1
1
1
2
Hold
20
20
16
8
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
42
36
27
21
Each month's total comprises the sum of three months' worth of ratings.
RGNX Financial Forecast
RGNX Stock Forecast FAQ
What is RGNX’s average 12-month price target, according to analysts?
Based on analyst ratings, RegenXBio’s 12-month average price target is 24.25.
What is RGNX’s upside potential, based on the analysts’ average price target?
RegenXBio has 82.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RGNX a Buy, Sell or Hold?
RegenXBio has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is RegenXBio’s price target?
The average price target for RegenXBio is 24.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $14.00. The average price target represents 82.88% Increase from the current price of $13.26.
The highest analyst price target is $37.00 ,the lowest forecast is $14.00. The average price target represents 82.88% Increase from the current price of $13.26.
What do analysts say about RegenXBio?
RegenXBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of RGNX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.